Complete Listing of the Claims

This listing of claims will replace all prior versions, and listings, of claims in this application.

Claims 1- 19 (Canceled)

20. (Currently amended) A pharmaceutical composition comprising:

(a) *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine dihydrochloride;

(b) a buffering agent; and

(c) water;

wherein the buffering agent is present in an amount sufficient to maintain ~~provide~~ the composition at [with] a pH in the range of about 5 to about 5.5 and wherein the composition is stable upon storage ~~between about 4 and about 6~~.

21. Canceled

22. (Original) The pharmaceutical composition of Claim 20 where the buffering agent comprises a citrate species.

23. (Original) The pharmaceutical composition of Claim 20 wherein the composition is isotonic.

24. (Original) The pharmaceutical composition of Claim 23 wherein the composition further comprises a sufficient amount of sodium chloride to render the composition isotonic.

25. (Original) The pharmaceutical composition of Claim 20, wherein the composition further comprises a surfactant.

26. (Original) The pharmaceutical composition of Claim 20, wherein the composition further comprises a therapeutically effective amount of one or more other therapeutic agents.

27. (Canceled)

28. (Withdrawn – currently amended) A process for preparing [a] the pharmaceutical composition of Claim 20 ~~for use in a nebulizer~~, the process comprising the steps of:

(a) dissolving crystalline *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine dihydrochloride in an acidic aqueous solution comprising a buffering agent; and

(b) adding a base until the composition has a pH of between about 5 and about 5.5 ~~4 and about 6~~.

29. (Withdrawn) The process of Claim 28 wherein the acidic aqueous solution is an isotonic solution.

30. (Withdrawn) The process of Claim 28 wherein step (b) comprises adding NaOH until the composition has a pH in the range of between about 5 and about 5.5.

Claims 31-40 (Canceled)

41. (New) The pharmaceutical composition of Claim 22 wherein the percentage of *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-formamido-4-hydroxyphenyl)ethylamine remaining in the composition after storage for four months at 25 °C is greater than about 95 %.

42. (New) The pharmaceutical composition of Claim 22 wherein the amount of *N*-{2-[4-((*R*)-2-hydroxy-2-phenylethylamino)phenyl]ethyl}-(*R*)-2-hydroxy-2-(3-

formamido-4-hydroxyphenyl)ethylamine remaining in the composition after storage for nine months at 5 °C is essentially unchanged.

43. (New) The process of Claim 29 wherein the acidic aqueous solution is an aqueous solution comprising citric acid and 0.9 % sodium chloride.